

Issue 22: February 2025

Half of cancer-related approvals were in England!

This newsletter summarises final decisions from HTA bodies around the world from published reports in February 2025.

Good news for: **Durvalumab**, approved for first-line metastatic lung cancer in England and Scotland; **Elacestrant**, approved for locally advanced ER+ HER2-breast cancer in England and no submission needed in Wales; and **Selpercatinib**, approved for RET+ advanced thyroid cancer and RET+ NSCLC in England under a commercial arrangement.

Mixed news for: **Osimertinib**, approved under a commercial arrangement in England for NSCLC but not approved in Germany; and **Pembrolizumab**, approved for cervical cancer in France and Germany and for lung cancer in England under a commercial arrangement, but not approved for endometrial cancer in Germany.

Bad news for: **Burosumab**, not approved for X-linked hypophosphataemia in Brazil; **Lecanemab**, not approved for mild cognitive impairment in Scotland; and **Teprotumumab**, not approved for moderate to severe Graves' ophthalmopathy in France.

42 Approvals
17 with special arrangements
3 with orphan drug status

31 Not approved
6 Excluded submissions

8 Evidence reviews

HTANGEL

Issue 22: February 2025

Pharmacological Technologies



Brazil
CONITEC

Blood
Sickle cell disease
DEFERIPRONE

✓ Approved



Brazil
CONITEC

Cancer
Chronic myeloid
leukaemia
BUSOTINIB

✗ Not
approved



Wales
AWTTC 5159

Blood
Haemophilia
EFANESCTOCOG
ALFA

✗ Excluded



Scotland
SMC2719

Cancer
Cervical cancer
CEMIPLIMAB

✓ Approved



England
NICE TA1044

Blood
Sickle cell disease
EXAGAMGLOGENE
AUTOTEMCEL

✓ Approved
with special
conditions



England
NICE TA1041

Cancer
Lung cancer
DURVALUMAB WITH
ETOPOSIDE AND EITHER
CARBOPLATIN OR CISPLATIN

✓ Approved
with special
conditions



Brazil
CONITEC

Blood
Idiopathic
thrombocytopenic purpura
RITUXIMAB, DAPSONE
AND ROMIPILOSTIM

✓ Approved
with special
conditions



Scotland
SMC2734

Cancer
Lung cancer
DURVALUMAB WITH
ETOPOSIDE AND EITHER
CARBOPLATIN OR CISPLATIN

✓ Approved



HTANGEL

Issue 22: February 2025

Pharmacological Technologies



England
NICE TA1036

Cancer
Breast cancer
ELACESTRANT

Approved
with special
conditions



England
NICE TA1040

Cancer
Breast cancer
OLAPARIB

Approved
with special
conditions



Wales
AWTTC 5141

Cancer
Breast cancer
ELACESTRANT

Excluded



Scotland
SMC2737

Cancer
Breast cancer
OLAPARIB

Approved



Germany
IQWiG A24-108

Cancer
B-cell lymphoma
EPCORITAMAB

Not
approved



England
NICE TA1043

Cancer
Lung cancer
OSIMERTINIB

Approved
with special
conditions



France
HAS CTAP429

Cancer
Ovarian cancer, Fallopian tube
cancer, Peritoneal cancer
MIRVETUXIMAB
SORAVTANSINE

Approved



Germany
IQWiG A24-119

Cancer
Lung cancer
OSIMERTINIB

Not
approved



HTANGEL

Issue 22: February 2025

Pharmacological Technologies



Germany
IQWiG A24-77

Cancer
Lung cancer
OSIMERTINIB

Not approved



Germany
IQWiG A24-110

Cancer
Cervical cancer
PEMBROLIZUMAB

Approved



France
HAS AP440

Cancer
Cervical cancer
PEMBROLIZUMAB

Approved



Wales
AWTTC 4520

Cancer
Lung cancer
PEMBROLIZUMAB

Excluded



England
NICE TA1037

Cancer
Lung cancer
PEMBROLIZUMAB

Approved with special conditions



England
NICE TA1039

Cancer
Thyroid cancer
SELPERCATINIB

Approved with special conditions



Germany
IQWiG A24-111

Cancer
Endometrial cancer
PEMBROLIZUMAB

Not approved



England
NICE TA1038

Cancer
Thyroid cancer
SELPERCATINIB

Approved with special conditions



HTANGEL

Issue 22: February 2025

Pharmacological Technologies



England
NICE TA1042

Cancer
Lung cancer
SELPERCATINIB



Wales
AWTTC 4642

Eye
Age-related macular
degeneration, Diabetic
macular oedema
AFLIBERCEPT



Germany
IQWiG G24-32

Cancer
Stomach cancer,
Gastroesophageal
junction cancer
ZOLBETUXIMAB



Scotland
SMC2720

Eye
Glaucoma, Ocular
hypertension
NETARSUDIL PLUS
LATANOPROST



Wales
AWTTC 5207

Cancer
Gastric cancer,
Gastroesophageal
junction cancer
ZOLBETUXIMAB



France
HAS CTAP416

Eye
Graves'
ophthalmopathy
TEPROTUMUMAB



France
HAS CTAP439

Cardiovascular
Pulmonary arterial
hypertension
SOTATERCEPT



Brazil
CONITEC

Genetic & Metabolic
X-linked
hypophosphatemia
BUROSUMAB



HTANGEL

Issue 22: February 2025

Pharmacological Technologies



Germany
IQWiG A25-02

Genetic & Metabolic
Diabetes
INSULIN ICODEC



Argentina
IECS

Genitourinary
Overactive bladder
BOTULINUM TOXIN



Brazil
CONITEC

Genetic & Metabolic
Fabry disease
MIGALASTAT



Argentina
IECS

Genitourinary
Overactive bladder
BOTULINUM TOXIN



Argentina
IECS

Genetic & Metabolic
Noonan syndrome
RECOMBINANT HUMAN
GROWTH HORMONE



Wales
AWTTC 3642

Genitourinary
Endometriosis
RELUGOLIX/ESTRADIOL/
NORETHISTERONE




France
HAS CTAP445

Genetic & Metabolic
Amyloidosis
VUTRISIRAN



Scotland
SMC2718

Infection
Human
immunodeficiency virus
CABOTEGRAVIR



HTANGEL

Issue 22: February 2025

Pharmacological Technologies



Germany
IQWiG G24-34

Infection
Bacterial infections
CEFTAZIDIME/
AVIBACTAM



Brazil
CONITEC

Infection
Respiratory syncytial
virus
NIRSEVIMAB



Wales
AWTTC 2566

Infection
Human
immunodeficiency virus
EMTRICITABINE/
TENOFVIR ALAFENAMIDE



Brazil
CONITEC

Infection
Respiratory syncytial
virus
RESPIRATORY SYNCYTIAL
VIRUS VACCINE



Brazil
CONITEC

Infection
Influenza
INFLUENZA VACCINE



Canada
CDA RC1564

Mental Health
Depression
BUPROPION



Germany
IQWiG G24-33

Infection
Bacterial infections
MEROPENEM/
VABORBACTAM



Brazil
CONITEC

Neurology
Alzheimer's disease
DONEPEZIL



HTANGEL

Issue 22: February 2025

Pharmacological Technologies



Scotland
SMC2723

Neurology
Lennox-Gastaut
syndrome
FENFLURAMINE

Approved
with special
conditions



Canada
CDA RC1570

Other
Opioid dependency
CRUSHED
BUPRENORPHINE-
NALOXONE

Not
approved



England
NICE TA1033

Neurology
Epilepsy
GANAXOLONE

Not
approved



Germany
IQWiG A24-118

Respiratory
Chronic obstructive
pulmonary disease
DUPILUMAB

Approved
with special
conditions



Scotland
SMC2700

Neurology
Alzheimer's disease
LECANEMAB

Not
approved



Germany
IQWiG A24-79

Respiratory
Chronic obstructive
pulmonary disease
DUPILUMAB

Not
approved



France
HAS AP424

Neurology
Friedreich's ataxia
OMAVELOXOLONE

Approved



Germany
IQWiG A24-112

Skin
Psoriasis
APREMILAST

Not
approved



HTANGEL

Issue 22: February 2025

Pharmacological Technologies



Brazil
CONITEC

Skin
Atopic dermatitis
METHOTREXATE

 **Approved**



Brazil
CONITEC

Skin
Atopic dermatitis
MOMETASONE
FUROATE

 **Approved**



Brazil
CONITEC

Skin
Atopic dermatitis
TACROLIMUS

 **Approved**



HTANGEL

Issue 22: February 2025

Non-pharmacological Technologies



England
NICE HTE12

Cancer

Lung cancer

ARTIFICIAL INTELLIGENCE-
DERIVED SOFTWARE



Brazil
CONITEC

Endocrine

Exocrine pancreatic
insufficiency

ENDOSCOPIC
ULTRASONOGRAPHY



Spain
OSTEBA E-25-01

Cancer

Lung cancer

PERCUTANEOUS CT-
GUIDED ABLATION



Brazil
CONITEC

Endocrine

Exocrine pancreatic
insufficiency

FECAL ELASTASE



Brazil
CONITEC

Cardiovascular

Arrhythmias

CONTACT FORCE
CATHETER



Argentina
IECS

Eye

Dry eye

CORNEAL AMNIOTIC
MEMBRANE GRAFTS



England
NICE IPG802

Cardiovascular

Coronary atherosclerosis

INTRAVASCULAR
LITHOTRIPSY



Argentina
IECS

Genitourinary

Benign prostatic
hypertrophy

BIPOLAR TRANSURETHRAL
ENUCLEATION



HTANGEL

Issue 22: February 2025

Non-pharmacological Technologies



Canada
CDA RC1568

Musculoskeletal
Plantar fasciitis, Pes
planus
SUBTALAR JOINT
ATHROEREISIS



Argentina
IECS

Surgery
Sinus surgery
MICRODEBRIDER



Argentina
IECS

Neurology
Tremor
MAGNETIC RESONANCE-
GUIDED FOCUSED
ULTRASOUND



Korea
NECA HTA-2025-8

Surgery
MOBILE SPUTUM
SUCTION MACHINE



Argentina
IECS

Neurology
Parkinson's disease
MAGNETIC RESONANCE-
GUIDED FOCUSED
ULTRASOUND



England
NICE HTE19

Respiratory
Chronic obstructive
pulmonary disease
DIGITAL TECHNOLOGIES



HTANGEL

Issue 22: February 2025

Diagnostic Testing



Korea
NECA RR-2025-2

Cancer
Oesophageal cancer

NEAR-INFRARED
INDOCYANINE GREEN
ANGIOGRAPHY



Brazil
CONITEC

Cancer
Oesophageal cancer

POSITRON EMISSION
TOMOGRAPHY-COMPUTED
TOMOGRAPHY



Argentina
IECS

Cardiovascular
Coronary artery disease

OPTICAL COHERENCE
TOMOGRAPHY



Korea
NECA RR-2025-1

Gastrointestinal
**Liver disease, Gallbladder
disease**

NEAR-INFRARED
INDOCYANINE GREEN
HEPATOGRAPHY AND BILIARY
TRACT IMAGING



Korea
NECA HTA-2025-7

Mental Health
Anxiety, Phobia
DENTAL ANXIETY
FEAR INDEX



Brazil
CONITEC

Neurology
**Neuromyelitis optica
spectrum disorder**
**ANTI-AQUAPORIN 4 ANTIBODY
DETECTION TEST**



HTANGEL

Issue 22: February 2025

Other Guidance



Switzerland
FOPH

Blood
Folic acid deficiency
FOLIC ACID TESTS



USA
AHRQ

Mental Health
Mental disorder, Occupational stress
SYSTEMATIC REVIEW ON MENTAL HEALTH AND OCCUPATIONAL STRESS



Japan
C2H

Cardiovascular
Aneurysms
AORTIC STENT GRAFT



Switzerland
FOPH

Other
Meniere's disease, Dizziness, Tinnitus
BETHAHISTINE OR CINNARIZINE



Canada
CDA OS0001

Gastrointestinal
Diverticulitis
OPIOID




Ireland
HIQA

Respiratory
Asthma
PROTOCOL REVIEW



Ireland
HIQA

Genetic & Metabolic
Obesity
PROTOCOL REVIEW



Japan
C2H

Skin
Alopecia areata
RITLECITINIB




HTANGEL

Issue 22: February 2025

Further Information

HTAngel is designed to help keep you up to date with the latest HTA decisions around the world. Below is a breakdown of the tiles in the newsletter.



At Crystallise we aim to provide an innovative approach to processing information, using software tools to automate processes that are slower and less accurate when done by humans. Our approach provides clients with greater transparency and scope than they could find for the same budget elsewhere. We work with a network of experts and organisations that help us support clients efficiently and effectively, and are proud of our flexible and ingenious way of solving their problems.

For further information about HTAngel contact newsletter@crystallise.com

To speak to us about our services contact contact@crystallise.com

